Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1
Journal of Clinical Oncology · 20.08.2026 · 44 (24) · 2278-2289
DOI: 10.1200/jco-25-02705 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.08.2026. Verfasst von Birgitte V Offersen und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Breast Neoplasms, Radiation Dose Hypofractionation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Adjuvant radiotherapy for node-positive breast cancer (BC) using 50Gy/25fx has been Danish Breast Cancer Group (DBCG) standard. Hypofractionated radiotherapy based on 40Gy/15fx has been increasingly used; however, it is less frequently for locoregional therapy because of concern over more morbidity. DBCG Skagen trial 1 hypothesized that 40Gy/15fx did not cause more lymphedema than 50Gy/25fx 3 years after radiotherapy without compromising the pattern of failure. METHODS Skagen trial 1 is a phase III, noninferiority trial randomly assigning high-risk BC patients with an indication for locoregional radiotherapy to standard 50Gy/25fx versus experimental 40Gy/15fx. The primary end point was arm lymphedema; assuming a 3-year incidence with 50Gy/25fx of 10%, noninferiority was predefined to maximum 5% excess incidence with 40Gy/15fx. Accrual continued until 3-year estimates were reported in 1,012 patients. RESULTS Between 2015 and 2021, 2,963 patients consented from 17 centers; the intention-to-treat cohort comprised 2,908 patients: 1,444 had 50Gy (50%), and 1,464 had 40Gy (50%). The median age was 57 years (range, 23-86). At a median follow-up of 4.1 years (IQR, 3.0-5.0), the 3-year rates of lymphedema were 9.4% (50Gy) versus 8.0% (40Gy), odds ratio 0.84 (95% CI, 0.62 to 1.14), and P = .27, thus within the +5-percentage-point noninferiority margin. The median follow-up for cancer outcomes was 5.25 years (IQR, 4.26 to 6.96). Within 8 years, the hazard ratio for locoregional recurrence was 0.96 (95% CI, 0.62 to 1.51), that for distant recurrence was 1.10 (95% CI, 0.89 to 1.37), that for BC mortality was 1.25 (95% CI, 0.93 to 1.66), and that for all-cause mortality was 1.08 (95% CI, 0.85 to 1.36), thus all with no differences by random assignment. CONCLUSION 40Gy/15fx for locoregional radiotherapy of BC did not result in more lymphedema compared with 50Gy/25fx. There were no differences in locoregional or distant recurrences, breast cancer mortality, nor all-cause mortality between the random assignment arms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.
- Aarhus University, Aarhus, Denmark.
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Oncology, Lillebaelt Hospital, Vejle, Denmark.
- Department of Oncology, Odense University Hospital, Odense, Denmark.
- Department of Oncology, Stavanger University Hospital, Stavanger, Norway.
ORCID-Profile: Birgitte V Offersen, Kristine Høgsbjerg, Carine Kirkove, Mechthild Krause, Louise W Matthiessen, Camilla Kronborg, Trine Tramm, Maj-Britt Jensen, Jens Overgaard
Zitieren
APA
Offersen, B. V., Alsner, J., Høgsbjerg, K., Nielsen, H. M., Maae, E., Nielsen, M. H., Mjaaland, I., Maraldo, M. V., Kirkove, C., Lörincz, T., Al-Rawi, S., Blix, E. S., Schreiber, A., Krause, M., Kasti, U. M., Matthiessen, L. W., Kronborg, C., Tramm, T., Jensen, M. B., …, & DBCG RT Committee (2026). Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1. Journal of Clinical Oncology, 44(24), 2278-2289. https://doi.org/10.1200/jco-25-02705
Vancouver
Offersen BV, Alsner J, Høgsbjerg K, Nielsen HM, Maae E, Nielsen MH, et al. Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1. Journal of Clinical Oncology. 2026;44(24):2278-2289. doi:10.1200/jco-25-02705
BibTeX
@article{Offersen2026,
author = {Offersen, Birgitte V and Alsner, Jan and Høgsbjerg, Kristine and Nielsen, Hanne M and Maae, Else and Nielsen, Mette H and Mjaaland, Ingvil and Maraldo, Maja V and Kirkove, Carine and Lörincz, Tamas and Al-Rawi, Sami and Blix, Egil S and Schreiber, Andreas and Krause, Mechthild and Kasti, Unn-Miriam and Matthiessen, Louise W and Kronborg, Camilla and Tramm, Trine and Jensen, Maj-Britt and Overgaard, Jens and DBCG RT Committee, DBCG RT Committee},
title = {Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {24},
pages = {2278--2289},
doi = {10.1200/jco-25-02705}
}
EUVIMED